<DOC>
	<DOCNO>NCT02918747</DOCNO>
	<brief_summary>Extranodal natural killer/T-cell lymphoma ( ENKTL ) aggressive subtype non-Hodgkin 's lymphoma show extremely poor survival . Several retrospective study singe-arm prospective phase 2 study show pegaspargase combine Gemox CHOP regimen achieve promising efficacy treatment ENKTL . However , prospective study compare efficacy two regimen . This prospective pilot study compare efficacy safety P-Gemoxd chemotherapy regimen P-CHOP regimen stage IE IIE ENKTL .</brief_summary>
	<brief_title>PEG-ASP+Gemoxd vs. PEG-ASP+CHOP First-line Chemotherapy Treatment NK/T-cell Lymphoma With Early Stage</brief_title>
	<detailed_description>Treatment PA-Gemoxd dosage follow : day 1 5 , 30-min intravenous infusion 800 mg/m2 gemcitabine ; day 1 , 2-h intravenous infusion 85 mg/m2 oxaliplatin ; day 1 , deep intramuscular injection 2000 U/m2 PEG-ASP two different site ; d1-5 , intravenous infusion 15mg dexamethasone . The regimen repeat every 3 week four cycle follow involved-field radiotherapy get CR , PR SD . Three-dimensional conformal radiotherapy do linear accelerator 2.0 gray ( Gy ) per daily fraction 5-6 week . The involved- field radiation ( IFRT ) dose 50-56 Gy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1. pathologically confirm , previously untreated ENKTL stage I/II ( stage I , patient one follow risk factor : EBVDNA &gt; upper limit normal , lesion beyond nasal , fever , LDH elevation ) ; 2. age range 18 70 year ; 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; 4. least one measurable lesion ; 5. adequate haematologic function ( haemoglobin &gt; 8.0 g/l , absolute neutrophil count &gt; 1500/ml , platelet &gt; 75,000/l ) , 6. adequate hepatic function ( total serum bilirubin ≤ 1.5 time upper limit normal , alanine aminotransferase aspartate aminotransferase ≤ 2.5 time upper limit normal ) , 7 . Hepatitis B virus carrier normal HBVDNA copy use antiviral drug . For patient elevated HBVDNA , use antiviral drug HBVDNA decrease &lt; upper limit normal . 8. adequate renal function ( serum creatinine ≤ 1.5 mg/dl , creatinine clearance ≥ 50 ml/min ) ; 9. normal coagulation function electrocardiogram result . 10 . Prior chemotherapy radiotherapy complete &gt; 4 week earlier , 11. willingness provide write informed consent . 1. mismatch inclusion criterion 2. systematic central nervous system involvement , previous concomitant malignancy coexist medical problem could cause poor compliance study protocol . 3. primary lesion upper respiratory</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>